News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. AB Sciex (d/b/a Sciex). (7/27/17).

AB Sciex (d/b/a Sciex). "Press Release: Sciex Equipment Is Now Available Through a Wide Range of Flexible Financing Packages via Evosciences". Warrington.27/07/2017The agreement with EVOSCIENCES enables analytical scientists working across all application areas, including life science research, pharmaceuticals, biologics, forensics, food testing and environmental analysis, to optimise the lifecycle of their SCIEX equipment.SCIEX, a global leader in life science analytical technologies, and EVOSC


2. AstraZeneca plc. (7/31/17).

AstraZeneca plc. "Press Release: Imfinzi Granted Breakthrough Therapy Designation by US FDA for Patients with Locally-advanced Unresectable Non-small Cell Lung Cancer".31-07-2017Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three yearsAstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatmen


3. Redx Pharma plc (in administration). (7/31/17).

Redx Pharma plc (in administration). "Press Relase: Disposal of BTK Inhibitor Drug Development Program". 31/07/2017Redx, the drug discovery and development company, announces that Jason Baker and Miles Needham of FRP Advisory LLP, joint administrators of the Company and of its subsidiary, Redx Oncology Limited, has entered into an unconditional agreement (on behalf of the Companies) on Friday 28 July 2017 for the disposal to Loxo Oncology, Inc., the US-based NASDAQ-quoted biopharmaceutical


4. Oxford BioMedica plc. (8/7/17).

Oxford BioMedica plc. "Press Release: Oxford BioMedica Announces MHRA Licence For Commercial Supply". London. 07/08/2017Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that it has been granted a Manufacturer/Importer License (MIA), from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”), to manufacture and distribute lentiviral vector material for commercial supply


5. Oxford BioMedica plc. (8/11/17).

Oxford BioMedica plc. "Press Release: Oxford BioMedica Announces a £2 Million Two-year Collaboration Co-funded by Innovate UK". London. 11/08/2017The agreement is to explore a next generation gene and cell therapy manufacturing platform for clinical and commercial applicationsOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it has agreed, as lead partner, to enter into a collaboration agreem



Page 29 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018